Get the Stockscreener App
278.17
5.14%
13.60
Illumina Inc stock is traded at $278.17, with a volume of 1.89M.
It is up +5.14% in the last 24 hours and up +35.69% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$264.57
Open:
$268.21
24h Volume:
1.89M
Relative Volume:
0.64
Market Cap:
$42.00B
Revenue:
$4.39B
Net Income/Loss:
$853.00M
P/E Ratio:
50.49
EPS:
5.5097
Net Cash Flow:
$556.00M
1W Performance:
+1.88%
1M Performance:
+35.69%
6M Performance:
+124.93%
1Y Performance:
+188.41%
1-Day Range:
$265.25
$278.59
1-Week Range:
$254.00
$309.35
52-Week Range:
$88.00
$309.35
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
278.17 | 42.00B | 4.39B | 853.00M | 556.00M | 5.5097 |
TMO
Thermo Fisher Scientific Inc
|
658.02 | 243.30B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
219.81 | 154.52B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
400.71 | 57.76B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
170.54 | 48.08B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
259.88 | 42.78B | 16.63B | 1.39B | 2.12B | 8.0674 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-26 | Resumed | UBS | Buy |
| Jun-26-26 | Resumed | Bernstein | Mkt Perform |
| Jun-10-26 | Upgrade | JP Morgan | Neutral → Overweight |
| May-15-26 | Resumed | RBC Capital Mkts | Outperform |
| May-14-26 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.
RBC raises target for Illumina stock to USD 310 - AD HOC NEWS
Illumina (ILMN) Shares Skyrocket, What You Need To Know - Yahoo Finance
Illumina (ILMN) Shares Skyrocket, What You Need To Know - FinancialContent
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina stock gains 7.95 percent as RBC raises target - AD HOC NEWS
Illumina Inc Stock (ILMN) Moved Up by 7.85% on Oct 5: Drivers Behind the Movement - TradingKey
Illumina rises as recent analyst target hikes and index inclusion keep momentum intact - Quiver Quantitative
Illumina stock hits 52-week high at 280.44 USD By Investing.com - Investing.com South Africa
Illumina stock hits 52-week high at 280.44 USD - Investing.com
Illumina's Clinical Sequencing Revenue Seen as Durable Mid-Teens Grower, RBC Capital Markets Says - marketscreener.com
Illumina's Clinical Sequencing Revenue Seen as Durable Mid-Teens Grower, RBC Capital Markets Says - Yahoo Finance
RBC Capital raises Illumina stock price target on clinical sales - Investing.com
RBC Capital maintains Outperform rating on Illumina, $310 price target - TradingView
RBC raises target for Illumina stock to USD 310 - AD HOC NEWS
Illumina Inc : RBC Raises Target Price to $31 - Moomoo
Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR - GlobeNewswire Inc.
Form 4 Illumina Inc For: 2 October By Investing.com - Investing.com South Africa
A director receives 107 shares instead of cash for quarterly retainer fees at Illumina (ILMN). - Stock Titan
A director receives stock for 100% of Q3 retainer fees at Illumina (ILMN) - Stock Titan
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina, Inc. (ILMN) Stock Forecasts - Yahoo Finance
Illumina Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
3 Reasons to Buy Grail (GRAL) Hand Over Fist in October - The Motley Fool
The Benchmark Matters: Evaluating TruPath Genome Beyond Individual Loci - Illumina
Where Will Illumina Stock Be in 5 Years If Its AI Bet Pays Off? - The Motley Fool
REGN or ILMN: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Is the Options Market Predicting a Spike in Illumina Stock? - Yahoo Finance
Illumina Inc. stock underperforms Friday when compared to competitors - MarketWatch
Illumina stock adds 3.20 percent ahead of the open - AD HOC NEWS
Will Index Reshuffle Change Illumina (ILMN) Narrative - simplywall.st
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today - Benzinga
Illumina stock holds near its yearly high as targets diverge - AD HOC NEWS
Illumina stock heads into the open after a 2.27 percent drop - AD HOC NEWS
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate - Zacks Investment Research
Illumina, Inc. (ILMN) Stock Analysis: Navigating a Complex Landscape with High Growth Potential - DirectorsTalk Interviews
Illumina, Inc.(NasdaqGS: ILMN) added to S&P 500 Equal Weighted - marketscreener.com
Illumina, Inc.(NasdaqGS: ILMN) added to S&P 500 Growth - marketscreener.com
Illumina, Inc.(NasdaqGS: ILMN) added to S&P 500 Health Care - marketscreener.com
Illumina, Inc.(NasdaqGS: ILMN) dropped from S&P 400 Health Care - marketscreener.com
Illumina Stock Drops 2.3% Before Monday’s S&P 500 Return; Volume Jumps Ninefold - TechStock²
Illumina Stock Is Up 133% This Year. Here’s Where It Could Go Further. - TIKR.com
Illumina Inc. stock underperforms Friday when compared to competitors - MarketWatch
Illumina Names Chief Commercial Officer and Chief Legal Officer - Medical Product Outsourcing
Illumina, Inc.(NasdaqGS: ILMN) dropped from Russell Small Cap Comp Value Index - marketscreener.com
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Illumina Inc Stock (ILMN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Corvex Management LP | Affiliate of Director (1) |
Sep 04 '26 |
Proposed Sale |
213.25 |
150,000 |
31,987,500 |
0 |
| Meister Keith A. | Director |
Sep 03 '26 |
Sale |
218.23 |
75,951 |
16,574,481 |
889,851 |
| Meister Keith A. | Director |
Sep 02 '26 |
Sale |
213.28 |
68,108 |
14,526,254 |
965,802 |
| Corvex Management LP | Affiliate of Director (1) |
Aug 27 '26 |
Proposed Sale |
224.84 |
200,000 |
44,968,000 |
0 |
| Meister Keith A. | Director |
Aug 27 '26 |
Sale |
228.89 |
138,379 |
31,673,778 |
1,033,910 |
| Meister Keith A. | Director |
Aug 26 '26 |
Sale |
225.46 |
106,543 |
24,021,247 |
1,172,289 |
| Corvex Management LP | Affiliate of Director (1) |
Aug 25 '26 |
Proposed Sale |
223.22 |
300,000 |
66,966,000 |
0 |
| Meister Keith A. | Director |
Aug 25 '26 |
Sale |
225.51 |
131,019 |
29,546,639 |
1,278,832 |
| Meister Keith A. | Director |
Aug 21 '26 |
Sale |
217.96 |
299,336 |
65,243,445 |
1,409,851 |
| Corvex Management LP | Affiliate of Director (1) |
Aug 21 '26 |
Proposed Sale |
213.24 |
250,000 |
53,310,000 |
0 |
1.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):